Search company, investor...

Endotis Pharma

endotis.com

Founded Year

2003

Stage

Series B | Alive

Total Raised

$36.5M

Last Raised

$36.5M | 15 yrs ago

About Endotis Pharma

Endotis Pharma is A specialty discovery and development company developing small glycol drugs for thrombosis and oncology

Headquarters Location

70 Rue du Docteur Yersin

59120,

France

Missing: Endotis Pharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Endotis Pharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Endotis Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Endotis Pharma is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

838 items

Endotis Pharma Patents

Endotis Pharma has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/17/2010

2/16/2016

Dosage forms, EC 2.4.1, Drug delivery devices, Prodrugs, Excipients

Grant

Application Date

12/17/2010

Grant Date

2/16/2016

Title

Related Topics

Dosage forms, EC 2.4.1, Drug delivery devices, Prodrugs, Excipients

Status

Grant

Endotis Pharma Frequently Asked Questions (FAQ)

  • When was Endotis Pharma founded?

    Endotis Pharma was founded in 2003.

  • What is Endotis Pharma's latest funding round?

    Endotis Pharma's latest funding round is Series B.

  • How much did Endotis Pharma raise?

    Endotis Pharma raised a total of $36.5M.

  • Who are the investors of Endotis Pharma?

    Investors of Endotis Pharma include NIF SMBC Ventures, Endeavour Vision, Sofinnova Partners, Wellcome Trust, Eurasante and 4 more.

  • Who are Endotis Pharma's competitors?

    Competitors of Endotis Pharma include Zealand Pharma, Kiadis Pharma, Solasia Pharma, Ikaria, Marinus Pharmaceuticals and 13 more.

Compare Endotis Pharma to Competitors

S
SBIO Pte

SBIO is focused on the discovery and development of small molecule oncology drugs.

A
Allostera

Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers.

M
Metronome Therapeutics

Metronome Therapeutics is developing oncology drugs

Metabolic Solutions Logo
Metabolic Solutions

Metabolic Solutions is working with a compound in the same class of drugs as two well-known diabetes medications -- Actos and Avandia which combined for sales of more than $5 billion in 2007. The firm says a potential drug Metabolic Solutions is testing now could be safer and more effective than Actos and Avandia.

O
OyaGen

OyaGen is a biotechnology company discovering, developing, and commercializing pharmaceutical therapies that seek to exploit RNA editing and DNA editing enzymes. The company will pursue several assays in high throughput screening strategies for drug development. OyaGen seeks to bring to market the anti-HIV drugs targeting Vif and APOBEC3G that solve the problems of viral resistance, a major shortcoming of all current therapies. In the long run, the Company will draw on its core expertise in Editing Enzyme technologies to develop therapies for other disease states.

E
Ethos Pharmaceuticals

Developer of novel variants of peptide drugs.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.